Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
completion around
Principal Investigator
by Steven C. Tsai, MD, PhD (ucla)
Headshot of Steven C. Tsai
Steven C. Tsai

Description

Summary

Official Title

A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy

Keywords

Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia, Cancer, Acute Myeloid Leukemia, AML, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Azacitidine, Venetoclax, Gilteritinib

Eligibility

Locations

  • Univ. of California - Irvine accepting new patients
    Irvine California 92697 United States
  • UCLA Medical Center accepting new patients
    Los Angeles California 90095 United States
  • City of Hope Nat'l Medical Center accepting new patients
    Duarte California 91010 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Astellas Pharma Global Development, Inc.
ID
NCT05520567
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 70 study participants
Last Updated